Neuropharmacology

Biography

Biography: Jerzy Leszek

Abstract

Alzheimer’s Disease (AD) is most common cause of dementia among people of aged 65 and older. The diagnosis of sporadic AD is based on clinical exclusion criteria and is only definite at necropsy. So, biochemical markers for AD would be of great value for its early diagnosis. During the last decade, research efforts have focused on developing CSF biomarkers for AD. The diagnosis performance of the CSF biomarkers: Tau protein, the 42-amino acid form of beta amyloid (ABeta 42) and amyloid precursor protein are of great importance. Since AD pathology is irreversible and present-day medications for AD only lower its associated symptoms, application of disease-modifying treatments could be successful only if AD early diagnosis is possible. The recently growing application of nanotechnology in molecular detection of biomarkers is promising for very early diagnosis of AD. From a practical point of view, one may perform a molecular detection process either inside the body (in vivo) or on the samples derived from the body (in vitro). In his presentation, author discuss the challenges of current treatment and diagnosis of AD and the development of biocompatible nanoparticles- provide the rational and potentials using nanoparticles for both drug carrier and imaging contrast agent for early diagnosis and treatment of AD and other neurodegenerative disorders like Parkinson Disease.